Meiji Seika Pharma launches first-in-human trial of Novel PD-1 agonist for autoimmune diseases
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
One task, one interaction, one pair, experts advocate
The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation
Giredestrant shows promise despite missing primary goal
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
Subscribe To Our Newsletter & Stay Updated